{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:48Z","timestamp":1791920088432,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40265-021-01594-y","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T06:04:21Z","timestamp":1631167461000},"page":"1781-1786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Odevixibat: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"5","key":"1594_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","volume":"14","author":"SJ Karpen","year":"2020","unstructured":"Karpen SJ, Kelly D, Mack C, et al. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020;14(5):677\u201389.","journal-title":"Hepatol Int"},{"key":"1594_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/liv.13306","volume":"37","author":"E de Vries","year":"2017","unstructured":"de Vries E, Beuers U. Management of cholestatic disease in 2017. Liver Int. 2017;37:123\u20139.","journal-title":"Liver Int"},{"issue":"2","key":"1594_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237\u201367.","journal-title":"J Hepatol"},{"key":"1594_CR4","unstructured":"Albireo Pharma. Bylvay (odevixibat) capsules, for oral use: US prescribing information. 2021. https:\/\/albireopharma.com. Accessed 21 Jul 2021."},{"key":"1594_CR5","unstructured":"Albireo AB. Bylvay: EU prescribing information. 2021. https:\/\/albireopharma.com. Accessed 21 Jul 2021."},{"key":"1594_CR6","unstructured":"FirstWorld Pharma. Albireo receives European marketing authorization of Bylvay (odevixibat), the first drug treatment for progressive familial intrahepatic cholestasis (PFIC) [media release]. 19 Jul 2021. https:\/\/www.firstwordpharma.com."},{"key":"1594_CR7","unstructured":"Albireo Pharma. Multimedia update\u2014Albireo announces FDA approval of Bylvay\u2122 (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis (PFIC) [media release]. 20 Jul 2021. https:\/\/ir.albireopharma.com."},{"key":"1594_CR8","unstructured":"U.S. Food and Drug Administration. Orphan drug designations and approvals. 2021. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=658118. Accessed 21 Jul 2021."},{"key":"1594_CR9","unstructured":"Albireo Pharma. Albireo granted orphan designation by European commission for lead product candidate A4250 for treatment of biliary atresia [media release]. 18 Dec 2018. http:\/\/www.albireopharma.com."},{"key":"1594_CR10","unstructured":"United States Securities and Exchange Commission. Form 10-K. Albireo Pharma, Inc. 2021. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001322505\/000155837021001730\/albo-20201231x10k.htm. Accessed 21 July 2021."},{"key":"1594_CR11","unstructured":"Albireo Pharma. Albireo reports Q4 and year-end 2020 financial results and business update [media release]. 25 Feb 2021. http:\/\/www.albireopharma.com."},{"key":"1594_CR12","unstructured":"Albireo Pharma. Albireo presents odevixibat commercialization road to $1 billion [media release]. 11 Feb 2021. www.albireopharma.com."},{"key":"1594_CR13","unstructured":"Albireo Pharma. Albireo reports Q1 financial results and business update [media release]. 6 May 2021. http:\/\/www.albireopharma.com."},{"key":"1594_CR14","unstructured":"Albireo Pharma. Albireo announces two new U.S. patents allowed for A4250 with term into 2031 [media release]. 16 May 2017. http:\/\/www.albireopharma.com."},{"issue":"2","key":"1594_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apt.13457","volume":"43","author":"H Graffner","year":"2016","unstructured":"Graffner H, Gillberg PG, Rikner L, et al. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1594_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","volume":"64","author":"A Baghdasaryan","year":"2016","unstructured":"Baghdasaryan A, Fuchs CD, \u00d6sterreicher CH, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64(3):674\u201381.","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"1594_CR17","first-page":"113","volume":"69","author":"PG Gillberg","year":"2019","unstructured":"Gillberg PG, Mattsson J, Torfgard K, et al. Clinical pharmacology of odevixibat, a potent, selective ileal bile acid transport inhibitor with minimal systemic exposure [abstract no. 167]. J Pediatric Gastroenterol Nutr. 2019;69(Suppl 2):113.","journal-title":"J Pediatric Gastroenterol Nutr."},{"issue":"Suppl 1","key":"1594_CR18","first-page":"S433","volume":"71","author":"P Stein","year":"2020","unstructured":"Stein P, Wright G, Kjems L, et al. Drug-drug interaction study to evaluate the interaction of A4250 (odevixibat) with itraconazole, a p-gp inhibitor in healthy adult subjects [abstract no. 638]. J Pediatric Gastroenterol Nutr. 2020;71(Suppl 1):S433\u20134.","journal-title":"J Pediatric Gastroenterol Nutr."},{"issue":"Suppl 1","key":"1594_CR19","first-page":"873","volume":"72","author":"P Stein","year":"2021","unstructured":"Stein P, Wright G, Kjems L, et al. Drug-drug interaction study to evaluate the interaction of A4250 (odevixibat) with midazolam, a sensitive CYP3A4 substrate, and itraconazole, a P-gp inhibitor, in healthy adult subjects [abstract no. H-ePwP-033]. J Pediatric Gastroenterol Nutr. 2021;72(Suppl 1):873\u20134.","journal-title":"J Pediatric Gastroenterol Nutr."},{"key":"1594_CR20","unstructured":"Thompson R, Baumann U, Czubkowski P, et al. Efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis types 1 and 2: results from PEDFIC 1, a randomized, double-blind, placebo-controlled phase 3 trial [abstract no. LO4]. The Liver Meeting Digital Experience\u2122. 2020. http:\/\/www.aasld.org\/event\/liver-meeting-digital-experience. Accessed 21 Jul 2021."},{"issue":"Suppl 1","key":"1594_CR21","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jval.2021.04.774","volume":"24","author":"RJ Thompson","year":"2021","unstructured":"Thompson RJ, Kjems L, Hardikar W, et al. Improved quality of life in children with progressive familial intrahepatic cholestasis following 24 weeks of treatment with odevixibat, an ileal bile acid transporter inhibitor: results from the phase 3 PEDFIC 1 study [abstract no. PMU62]. Value Health. 2021;24(Suppl 1):S155.","journal-title":"Value Health."},{"key":"1594_CR22","unstructured":"Thompson R, Artan R, D'Antiga L, et al. Long-term efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor in children with progressive familial intrahepatic cholestasis: interim results from PEDFIC 2, an open-label phase 3 trial [abstract no. LP19]. The Liver Meeting Digital Experience\u2122. 2020. http:\/\/www.aasld.org\/event\/liver-meeting-digital-experience. Accessed 21 Jul 2021."},{"issue":"Suppl 1","key":"1594_CR23","first-page":"819","volume":"72","author":"RJ Thompson","year":"2021","unstructured":"Thompson RJ, Verkade HJ, Gonzales E, et al. Long-term treatment benefits of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: improvements in total bilirubin, growth, and sleep as secondary and exploratory outcome measures from the phase 3 PEDFIC 1 and PEDFIC 2 studies [abstract no. H-O-030]. J Pediatric Gastroenterol Nutr. 2021;72(Suppl 1):819\u201320.","journal-title":"J Pediatric Gastroenterol Nutr"},{"key":"1594_CR24","unstructured":"Thompson R, Horn P, Houwen RHJ, et al. Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies [abstract no. PO-1665 plus poster]. In: International Liver Congress. 2021."},{"key":"1594_CR25","unstructured":"Thompson R, D'Antiga L, Kamath BM, et al. Rapid and durable effect of odevixibat on clinical and biochemical parameters of cholestasis in children with progressive familial intrahepatic cholestasis [abstract no. OS-1554]. In: International Liver Congress. 2021."},{"key":"1594_CR26","doi-asserted-by":"crossref","unstructured":"Thompson R, D'Antiga L, Gonzales E, et al. Odevixibat therapy improves clinically meaningful endpoints in children with progressive familial intrahepatic cholestasis: data from the PEDFIC 1 and PEDFIC 2 trials [abstract no. PO-1833 plus poster]. In: International Liver Congress. 2021.","DOI":"10.1016\/S0016-5085(22)63792-2"},{"key":"1594_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101751","author":"U Baumann","year":"2021","unstructured":"Baumann U, Sturm E, Lacaille F, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin Res Hepatol Gastroenterol. 2021. https:\/\/doi.org\/10.1016\/j.clinre.2021.101751.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1594_CR28","unstructured":"Grammatikopoulos T, Thompson C, Soufi N, et al. Long-term safety and tolerability of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: results from the phase 3 PEDFIC 1 and PEDFIC 2 studies [abstract no. H-O-011]. J Pediatric Gastroenterol Nutrition. 2021;72(Suppl 1):781\u20132."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01608-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01594-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T17:04:43Z","timestamp":1673197483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01594-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01594-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"9 September 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01608-9","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01608-9","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}